Organon & Co.
corporate_fare Company Profile
Organon & Co. (NYSE:OGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for OGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 10 rated 8 or above. Recent SEC coverage for OGN spans 10-Q, 8-K, DEFA14A, PREM14A.
Recent high-impact activity:
- Organon Q3 Revenue Slips 2% to $1.57B as Sun Pharma $14.00 Deal Nears Early-2027 Close
- Sun Pharma Prices Rs 10,000 Cr Bond Sale to Refinance Organon Deal Bridge Loans
- Organon's Hormone-Free IUD Shows 6-Year Efficacy; FDA Review of Extended Use Underway
- Organon Q2 2026: Material Weaknesses Remediated, Cash Surges to $1.1B on Jada Sale
- Organon Shareholders Approve $14/Share Sun Pharma Buyout with 98.7% Vote
Financial Snapshot
Short Interest & Short Volume
8.48 days to coverFINRA reported short interest of 19,693,671 shares in OGN as of the October 30, 2026 settlement, a 4.7% increase from the prior period — about 8.5 days to cover at its recent average daily volume. On November 20, 2026, 62.4% of OGN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.